PE20010665A1 - Una composicion farmaceutica de drospirenona y etinilestradiol para ser usada como anticonceptivo - Google Patents
Una composicion farmaceutica de drospirenona y etinilestradiol para ser usada como anticonceptivoInfo
- Publication number
- PE20010665A1 PE20010665A1 PE2000000895A PE0008952000A PE20010665A1 PE 20010665 A1 PE20010665 A1 PE 20010665A1 PE 2000000895 A PE2000000895 A PE 2000000895A PE 0008952000 A PE0008952000 A PE 0008952000A PE 20010665 A1 PE20010665 A1 PE 20010665A1
- Authority
- PE
- Peru
- Prior art keywords
- ethinylestradiol
- drospirenone
- pharmaceutical composition
- composition
- contraceptive
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003433 contraceptive agent Substances 0.000 title 1
- 230000002254 contraceptive effect Effects 0.000 title 1
- 229940007690 drospirenone and ethinylestradiol Drugs 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 3
- 229960002568 ethinylestradiol Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- 230000016087 ovulation Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a)UN AGENTE ACTIVO 6ß,7ß; 15ß,16ß-DIMETILEN-3-OXO-17O-PREGN-4-EN-21, 17-CARBOLACTONA (DROSPIRENONA, UTILIZANDOSE 2mg A 4mg; b)17O-ETINILESTRADIOL (ETINILESTRADIOL) UTILIZANDOSE 0,01 mg A 0,05mg; c)EXCIPIENTES QUE PROMUEVEN LA DISOLUCION RAPIDA DE LOS AGENTES ACTIVOS; LA COMPOSICION SE CARACTERIZA PORQUE LOS AGENTES SE ENCUENTRAN EN FORMA MICRONIZADA O PULVERIZADA EN UNA SOLUCION SOBRE PARTICULAS DE SOPORTE INERTE, EL 70% DE LAS SUSTANCIAS ACTIVAS ES LIBERADA DENTRO DE LOS 30 MINUTOS DESDE LA ADMINISTRACION DE LA MISMA. LA COMPOSICION PUEDE SER UTIL PARA INHIBIR LA OVULACION, TRATAR TRASTORNOS INDUCIDOS POR ANDROGENOS COMO ACNE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99202826 | 1999-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010665A1 true PE20010665A1 (es) | 2001-06-19 |
Family
ID=8240592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000895A PE20010665A1 (es) | 1999-08-31 | 2000-08-31 | Una composicion farmaceutica de drospirenona y etinilestradiol para ser usada como anticonceptivo |
Country Status (6)
| Country | Link |
|---|---|
| CN (1) | CN1879632A (es) |
| AR (2) | AR025443A1 (es) |
| CO (1) | CO5200771A1 (es) |
| EC (1) | ECSP003721A (es) |
| PE (1) | PE20010665A1 (es) |
| ZA (2) | ZA200201668B (es) |
-
2000
- 2000-08-30 AR ARP000104515A patent/AR025443A1/es not_active Application Discontinuation
- 2000-08-31 PE PE2000000895A patent/PE20010665A1/es not_active IP Right Cessation
- 2000-08-31 CO CO00065489A patent/CO5200771A1/es not_active Application Discontinuation
- 2000-08-31 CN CNA2005100992135A patent/CN1879632A/zh active Pending
- 2000-10-18 EC EC2000003721A patent/ECSP003721A/es unknown
-
2002
- 2002-02-27 ZA ZA200201668A patent/ZA200201668B/xx unknown
-
2004
- 2004-03-05 AR ARP040100696A patent/AR043470A2/es not_active Application Discontinuation
-
2005
- 2005-05-25 ZA ZA200404083A patent/ZA200404083B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR025443A1 (es) | 2002-11-27 |
| ZA200201668B (en) | 2004-06-24 |
| ECSP003721A (es) | 2002-05-23 |
| CO5200771A1 (es) | 2002-09-27 |
| AR043470A2 (es) | 2005-07-27 |
| CN1879632A (zh) | 2006-12-20 |
| ZA200404083B (en) | 2006-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP38008A (en) | Drospirenone for hormone replacement therapy | |
| BR0014159A (pt) | Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional | |
| AR031563A1 (es) | Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u | |
| BR9808888A (pt) | Formas de dosagem e método de melhorar disfunção erétil masculina | |
| MA26843A1 (fr) | NOUVELLES COMPOSITIONS ESTRO-PROGESTATIVES TOPIQUES à EFFET SYSTÉMIQUE | |
| CR7420A (es) | Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12 | |
| EP1429729A4 (en) | COMBINED METHOD OF FORMING WITH A CHOLESTERIC STRENGTH, A RENIN-ANGIOTENSIN-INHIBITOR AND ACETYL-SALICYLIC ACID | |
| BR0009437A (pt) | Amido pré-gelatinizado em uma formulação de liberação controlada | |
| PE20051038A1 (es) | Uso extendido de combinacion que comprende estrogenos y progestinas | |
| KR19990076685A (ko) | 게스타겐 및 에스트로겐의 배합을 포함하는 암컷 포유동물용 피임 방법 및 키트 | |
| PE20070208A1 (es) | Anticoncepcion oral con trimegestona | |
| PL402549A1 (pl) | Dopochwowa kompozycja farmaceutyczna i zastosowanie | |
| PE20070329A1 (es) | Composiciones con estrogenos y metodos terapeuticos para su uso | |
| NO327588B1 (no) | Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel | |
| AR036970A1 (es) | Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion | |
| AR045576A1 (es) | Composicion farmaceutica que comprende drospirenona y etinilestradiol | |
| Almen-Christensson et al. | Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study | |
| PE20010665A1 (es) | Una composicion farmaceutica de drospirenona y etinilestradiol para ser usada como anticonceptivo | |
| RU2000115313A (ru) | Схемы приема гестаген-анти-гестагена | |
| BRPI0606297A2 (pt) | medicamento peroral sólido para contracepção | |
| AR047782A1 (es) | Composiciones farmaceuticas solidas que comprenden una combinacion de drospirenona, etinilestradiol y un agente surfactante adecuado que presenta una homogeneidad de contenido y velocidad de disolucion asegurada para la droga no micronizada, procedimiento para preparar dicha composicion y uso de est | |
| CO5011086A1 (es) | Budesonida sola o en combinacion con acido ursodesoxicolico en la terapia de enfermedades colestasicas del higado | |
| CO5160244A1 (es) | Tabletas bioadhesivas de hidratacion progresiva | |
| AR035633A1 (es) | Drospirenona para terapia de reemplazo de hormonas | |
| Brackman | OESCLIM®: summary of tolerability and safety |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| MC | Annulment |